Drug
Upadacitinib
Upadacitinib: highest development phase Phase 3, developed by AbbVie. 2 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- AbbVie
Trials
| Drug | Phase | Indication |
|---|---|---|
| Upadacitinib NCT07896434 | Phase 3 | Non-Segmental Vitiligo |
| Upadacitinib NCT07670156 | Phase 1/2 | JAK1 GOF |
Latest
No recent events.
Follow Upadacitinib on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.